http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012126501-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate | 2010-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012126501-A |
| titleOfInvention | PHARMACEUTICAL COMPOSITION FOR PARENTERAL INTRODUCTION IN THE FORM OF SUSPENSION WITH LONG RELEASE IN A LOW AND VERY LOW DOSE FOR HORMONAL THERAPY OF CLIMACTERIC SYNDROME |
| abstract | 1. Pharmaceutical composition for parenteral administration in the form of a sustained release suspension containing suspended particles of estradiol and progesterone for hormone replacement therapy in female mammals in low and very low doses in the form of an injection suspension formed by estradiol particles, progesterone particles, surface an active agent, an isoosmotic agent, a viscosity increasing agent, and one or more preservatives. 2. The pharmaceutical composition for parenteral administration according to claim 1, wherein the particle size of estradiol is from 1 to 100 μm. The pharmaceutical composition for parenteral administration according to claim 1, wherein the particle size of the progesterone is from 1 to 100 microns. A pharmaceutical composition for parenteral administration according to claim 1, wherein the obtained product is a suspension. A pharmaceutical composition for parenteral administration according to any one of claims 1 to 4, wherein the product is used in a pharmaceutical form for parenteral administration. The pharmaceutical composition for parenteral administration according to claim 5, wherein the pharmaceutical form for parenteral administration is a pharmaceutical form for intramuscular administration. The pharmaceutical composition for parenteral administration according to claim 5, wherein the pharmaceutical form for parenteral administration is a pharmaceutical form for subcutaneous administration. The pharmaceutical composition for parenteral administration according to claim 5, wherein the pharmaceutical form for parenteral administration is a pharmaceutical form for intradermal administration. Pharmaceutical composition for � |
| priorityDate | 2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.